AnalysisNews

VRXA today

$1.04+$0.01 (+0.97%)close Nov 20, 2026

Trend

DailyNeutral

4 hourExpanding

1 hourStrong Bullish

15 minLeaning Bullish

5 minStrong Bearish

Key levels

Resistance$11.20

Resistance$10.01

Latest news & SEC filings

ProductVeraxa Biotech says lab tests support its BiTAC-ADC platform

SEC FilingVeraxa Biotech AG - Post de-SPAC filed an insider trading report (Form 4)

All VRXA news →

About Veraxa Biotech

Veraxa Biotech is a clinical-stage biotechnology company developing antibody-based cancer therapies. Its pipeline includes antibody-drug conjugates built on Click Chemistry ADC platforms and bispecific T-cell engager (BiTAC) platforms, with lead candidate VX-A901 in development for acute myeloid leukemia. The company operates through a Swiss parent and a German subsidiary, and pursues collaborations and partnerships with third parties to advance its product candidates.

Based on the company's 20-F filed Jun 16, 2026.

Nasdaq · Healthcare

Veraxa Biotech AG - Post de-SPAC (VRXA)

$1.04+0.01 (+0.97%)
WATCHLISTGrade: C+Risk: LOW
1D5D1M1Y5YMaxSign up for all timeframes
1.011.071.141.201.04Oct 20Oct 28Nov 5Nov 13
High1.06
Low1.03
Open1.04
Volume107K
Avg Vol160K
VWAP1.04
30d High1.26
30d Low0.95
30d Chg-8.77%

What Is the Price Target for VRXA?

SEPT Low Target

$0.00

SEPT Mid Target

$0.00

SEPT High Target

$0.00

Analyst Consensus

$0.00

Current: $0.95Upside: +0.0%Confidence: 20%Method: No Coverage

Is VRXA a Buy or Sell Right Now?

54
Investability Score
WATCHLIST12-18 months

Test your own strategy on VRXA

Describe your strategy in plain words, then scan, alert, backtest and paper trade it on VRXA with SEPT’s own market data.

Start Free Trial →

Is VRXA Overvalued or Undervalued?

Valuation Verdict

N/A

Methods Used

N/A

Fair Value

$N/A

5

Moat Score

NONE

0/9

Piotroski Score

N/A

Altman Z-Score

What Is Smart Money Doing with VRXA?

Insider Signal

NEUTRAL

1 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

LOW

Signal: NEUTRAL

Recent Insider Activity

NameTitleTypeSharesValueDate
Gruninger MarcdirectorBuy9,133$9KOct 28, 2026
Gruninger MarcdirectorBuy867$849.66Oct 27, 2026
Ziegler Christoph SamueldirectorBuy30,000$33KOct 20, 2026
Hosseinion WarrendirectorBuy6,024$10KSep 10, 2026

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See Smart Money Data →

VRXA Growth Story

Revenue YoY

N/A%

3yr Revenue CAGR

N/A%

EPS Growth YoY

N/A

FCF Growth YoY

N/A%

Revenue Trend

UNKNOWN

Dark Pool Trades for VRXA

PREVIEW

Recent off-exchange (dark pool) prints for VRXA: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.

TimePriceSizeValueSide
16:40:22$1.047,000$$7KSELL
16:36:10$1.051,000$$1KMIDPOINT
16:01:43$1.031,000$$1KSELL
16:00:48$1.031,000$$1KSELL
15:59:36$1.031,000$$1KSELL

5 dark pool trades shown · $$11K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Veraxa Biotech AG - Post de-SPAC (VRXA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...

Your strategy, tested before real money.

Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.

Try SEPT Free for 7 Days →

VRXA — frequently asked questions

What is VRXA stock price today?

Veraxa Biotech AG - Post de-SPAC (VRXA) is at $1.04, up 0.97% (+$0.01) at the Nov 20, 2026 close.

Why is VRXA stock moving today?

Latest VRXA news — Nov 15, 2026: Veraxa Biotech says lab tests support its BiTAC-ADC platform · Oct 21, 2026: Veraxa Biotech AG - Post de-SPAC filed an insider trading report (Form 4)

What are VRXA support and resistance levels?

Resistance: $10.01, $11.20.

What are insiders doing with VRXA?

Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.

What is the latest news on VRXA?

Nov 15, 2026: Veraxa Biotech says lab tests support its BiTAC-ADC platform · Oct 21, 2026: Veraxa Biotech AG - Post de-SPAC filed an insider trading report (Form 4)